Latest News and Updates

 

Subsidised Continuous Glucose Monitoring Products for Young Australians

From 1 April 2017, the Australian Government will provide fully subsidised continuous glucose monitoring (CGM) products to eligible children and young people aged under 21 years with type 1 diabetes.

Children and young people who experience significant challenges in managing their blood glucose levels, particularly those who have difficulty identifying symptoms of hypoglycaemia, will benefit the most from CGM technology.

This initiative allows families and children to better self-manage their blood glucose levels, reducing visits to emergency departments and missed school days.

Continuous glucose monitors will alert users or their parents/carers if glucose levels are getting too low or too high without the need for continuous finger prick tests, reducing stress and anxiety for the child and young person and their family.

To be eligible, the child or young person will need to be assessed by an authorised health professional to determine if they meet specific criteria and to ensure that the use of CGM is a suitable part of their diabetes management plan.

The authorised health professionals for CGM assessment are endocrinologists, credentialled diabetes educators, and other health professionals specialising in diabetes (physicians, paediatricians or nurse practitioners).

An expert CGM Advisory Group, including endocrinologists, credentialed diabetes educators, consumer experts and other diabetes stakeholder groups, has advised that the best clinical outcomes are achieved when CGM is used as part of an ongoing diabetes management plan. Authorised health professionals will also play a key role in assisting in the set up and operation of CGM devices for eligible children and young people not currently using CGM.

The Continuous Glucose Monitoring Eligibility Assessment form is available at www.ndss.com.au/cgm.

Further information about access to CGM products through the NDSS, please visit www.health.gov.au/ndss-cgm. You can also call the NDSS Helpline on 1300 136 588. Download the CGM Flow Chart for Health Professionals - PDF


2017 ADS Kellion Award

The Kellion Foundation and the Australian Diabetes Society invite applications for the Award for an Australian who has made an outstanding contribution in diabetes research, clinical or service areas in Australia.  This is an annual award and commenced in the year 2000.

Nominations are now called for this Award which will be considered by a review committee consisting of prominent Australian diabetes researchers with the power to co-opt international referees.  Nominations may be self-initiated, initiated by colleagues or by organisations.

The recipient of the Kellion Award must be an ADS member and will be required to deliver the ADS Kellion Plenary Lecture at the Australian Diabetes Society/Australian Diabetes Educators Association Annual Scientific Meeting to be held at the Perth Convention & Exhibition Centre, WA from 30 August - 1 September 2017.  The Award will include a return business class airfare to the meeting, accommodation for the duration of the meeting, registration, and a commemorative plaque.  There is also a A$10,000 honorarium.

Nominations should include a letter (not exceeding 2 pages) clearly stating the basis of the nomination and a full curriculum vitae.  Nominations made in the previous years have been retained and will be considered also.

Nominations Closing Date: Friday 28 April 2017

Please forward nominations or for further enquires to:-

Dr Sof Andrikopoulos
Australian Diabetes Society
145 Macquarie St
SYDNEY NSW 2000
Ph: 02 9256 5462
Fax: 02 9252 3668
Email: ceo@diabetessociety.com.au

Previous recipients of this prestigious award include:  Len Harrison (2000), Don Chisholm (2001), George Jerums (2002), Paul Zimmet (2003), Tim Welborn (2004), Mark Cooper (2005), David James (2006), Ted Kraegen (2007), Martin Silink (2008), Michael Horowitz (2009), Dennis Yue (2010), Frank Alford (2011), Joseph Proietto (2012), Peter Colman (2013), Timothy Davis (2014), Stephen Colagiuri (2015), Kerin O'Dea (2016)


Diabetes Australia Research Program Grants For 2018

Diabetes Australia is the national body for people affected by all types of diabetes. We are committed to reducing the impact of diabetes. This year the Diabetes Australia Research Program should provide over $3.6 million to vital diabetes research projects across Australia. Applications for the 2018 Grant Round are now open and projects across all areas of diabetes research will be considered. Projects focused on self-monitoring & self-management of diabetes, Aboriginal and Torres Strait Islanders and diabetes, and behavioural research are encouraged.

In 2018, grants may be awarded in the following categories:
• two $150,000 Millennium Awards - one for type 1 diabetes and one for type 2 diabetes; and
• an unspecified number of General Grants, up to $60,000 per grant

Applications Closing Date: Friday 5 May 2017


Applications forms and further information are available at www.diabetesaustralia.com.au/research (Please click here to download the flyer)


Ranji and Amara Wikramanayake Clincial Diabetes Research Award

This Mid-Career Award supporting the career of a clinical diabetes researcher has been made possible by the generosity of Dr Ranji Wikramanayake, a long standing member of the Australian Diabetes Society.

The Australian Diabetes Society invites applications for a Mid-Career Diabetes Research Award from endocrinology/diabetes clinicians who are members of the Australian Diabetes Society (ADS) and are between 6-15 years' post-doctoral degree.  Applications can be nominated by financial members of the ADS or by self nomination. 

The award is to recognise significant contributions to diabetes research by a clinician and to support further advancement of those achievements. 

The successful candidate will deliver the Ranji and Amara Wikramanayake Diabetes Award Lecture at the 2017 ADS/ADEA Annual Scientific Meeting to be held at the Perth Convention & Exhibition Centre from 30 August - 1 September 2017. In addition, the awardee will be required to provide a written report on their further achievements (projects, presentations, publications, funding, community engagement) within 18 months of accepting the award.

The award is for A$40,000 and will be presented at the conclusion of the award lecture along with a commemorative plaque.

The selection criteria are:

  • Is a clinician who has provided significant contributions to diabetes research
  • Is a financial member of the ADS
  • Is between 6-15 years post-doctoral degree
  • Is available to give the award lecture at the ADS/ADEA ASM in 2017

Applications, accompanied by a full curriculum vitae, are now invited and should be in the form of a letter not exceeding 2 pages outlining the applicant’s suitability for the award.

Applications should be emailed to Dr Sof Andrikopoulos, ADS CEO at ceo@diabetessociety.com.au

Applications Closing Date: Friday 26 May 2017


2017 ADS Jeff Flack Diabetes Data Award

The Australian Diabetes Society invites nominations for the 2017 ADS Jeff Flack Diabetes Data Award for an Australian researcher who has made an outstanding contribution to Diabetes data collection in Australia. The Award will be considered by a review committee consisting of prominent Australian diabetes researchers with the option to co-opt international referees.  The nominee must be a financial member of the ADS and have been a member for at least 12 months at the time of their nomination for this award.  At least one of the Nominator/s must be an ADS member and nominations can be self-initiated or initiated by colleagues.

Categories of merit include:

    • Multiple / Significant / Substantial Publications (or In Press) involving data collection, collation, analysis and reporting (beyond ‘routine day-to-day’ minimum dataset collection);
    • Something ‘Novel’ regarding data collection / reporting – development of data systems;
    • Substantial contribution to data issues (attendance / chair of Committee(s) on data issues – developing standards etc);
Nominations should include a letter (not exceeding 2 pages) clearly stating the basis of the nomination and a full curriculum vitae and be sent to:


Dr Sof Andrikopoulos
Chief Executive Officer
Australian Diabetes Society
145 Macquarie Street
SYDNEY   NSW   2000
Fax:  02-9252 3668
Email: ceo@diabetessociety.com.au 

Further enquiries can be directed to Dr Sof Andrikopoulos, CEO, ADS on telephone (02) 9256 5462 or email ceo@diabetessociety.com.au

Nominations Closing Date: Friday 30 June 2017


Australian Diabetes Society – Lifetime Achievement Award

Eligibility

The Lifetime Achievement Award recognises an individual who has:

  • An established history of distinguished service to education, clinical practice and/or research and training in diabetes
  • Made a lasting contribution to diabetes
  • Exhibited leadership and mentorship in diabetes research and/or clinical practice on a state, national and/or international level

Selection of the nominee is made on the basis of the candidate's significant, fundamental contributions to diabetes (whether in research, clinical practice, leadership, mentorship or other); the lasting impact of these contributions to the sector; and the demonstration of a lifetime commitment to diabetes.

Nominees must have:

  • Made a positive impact to diabetes [at either state/territory or national level]
  • The respect of professional peers
  • General acknowledgement as having reached a pinnacle of their profession
  • Demonstrated, over an extended period of time, a contribution which has included either research and/or clinical practice, professional leadership and service to the diabetes community
  • Held positions of leadership
  • Personal integrity
  • On-going membership with the ADS

Nominees will be recognised and the winner of the award will be announced at the Annual General Meeting held at Annual Scientific Meeting each year.

Nomination Process

Please submit two letters of recommendation including a full curriculum vitae of the nominee to the ADS CEO, Dr Sof Andrikopoulos via email: ceo@diabetessociety.com.au One letter of recommendation must be by a financial member of the ADS.

Nominations Closing Date: Friday 7 July 2017


15th ADS-John R Turtle Diabetes Clinical Skills Training Course for Advanced Trainees in Adult Endocrinology

The ADS John R Turtle Diabetes Clinical Skills Training Course is designed to be practical and interactive. It will be run by experienced clinical endocrinologists from across Australia and will focus on everyday clinical skills required in the treatment of diabetes by endocrinology trainees. The course is supported by the Specialist Advisory Committee (SAC) in Endocrinology from the Royal Australasian College of Physicians (RACP).

To honour Professor John R Turtle in his retirement, the ADS have resolved that the Course on an ongoing basis will be named The John R Turtle Diabetes Clinical Skills Training Course for Advanced Trainees in Endocrinology.

The 15th ADS John R Turtle Diabetes Clinical Skills Training Course will be held on Friday 1 September 2017 from 1:00pm to 5:30pm following the ADS/ADEA Annual Scientific Meeting at the Perth Convention & Exhibition Centre in WA.

(Please Note: This course is by invitation and is for Advanced Trainees in Adult Endocrinology ONLY)

Please contact Linda Valenzisi at the ADS Secretariat via email at: linda@diabetessociety.com.au if you have any enquiries regarding the course.

To register for the 15th ADS John R Turtle Diabetes Clinical Skills Training Course:

Please download the program for this year's ADS JRT Course - PDF

Registration for the course closes on Monday 17 July 2017 but early registration is encouraged as limited places are available. The ADS Secretariat will contact you in due course to confirm your registration. All trainees must also register for the ADS/ADEA Annual Scientific Meeting in Perth to attend the ADS JRT Course.

Click here to apply online for the 2017 ADS JRT Course

The Australian Diabetes Society gratefully acknowledges the genrous support from Servier and Sanofi of the 2017 ADS JRT Course.


ADS supports discussions on diabetes and Ramadan

In February 2017, the ADS and the NADC joined representatives from the Diabetes and Ramadan (DaR) International Alliance at this first-ever symposium in Australia. The event was an initiative of the Department of Endocrinology and Metabolism at Concord Repatriation General Hospital.

The event promoted the new IDF-DaR Diabetes and Ramadan Practical Guidelines, which provide healthcare professionals with important information to assist them in supporting patients during Ramadan.

A copy of the guidelines can be downloaded from the IDF website at http://www.idf.org/guidelines/diabetes-in-ramadan.

Many thanks to Sanofi who sponsored the production of the symposium videos. Please click the following link http://nadc.net.au/video/ to access the symposium videos via the National Association of Diabetes Centres (NADC) website and share with your colleagues.


ADS/ADEA Annual Scientific Meeting; 30 August - 1 September 2017, Perth, WA

The Australian Diabetes Society (ADS) and the Australian Diabetes Educators Association (ADEA) reaffirm their strong partnership as leaders in diabetes education, management and research at the 2017 Annual Scientific Meeting.

The exciting and innovative program will bring together national and international experts to promote the exchange of the latest clinical practices and cutting edge research in diabetes. State-of-the-Art lectures, free communication sessions and clinical and scientific educational symposia, will all be appreciated by the 2016 attendees.

Dates:

Wednesday 30 August to Friday 1 September 2017

Venue:

Perth Convention & Exhibition Centre, WA

Program:

The 2017 ADS/ADEA ASM provisional program is currently unavailable.

Please be advised the 2017 ADS/ADEA ASM will be extended into Friday afternoon. If you are planning to fly home on the Friday, please make suitable flight arrangements to ensure you don't miss the closing plenary session concluding at 4:00pm.

Registration:

Registrations are now open for the 2017 ADS/ADEA Annual Scientific Meeting. Please visit the ASM website at http://www.ads-adea.org.au/registration/ to register.

Abstract Submission:

Abstract Submission is now open for the 2017 ADS/ADEA Annual Scientific Meeting. ADS categories for abstract submission are Basic Science or Clinical Science. Abstract submissions close on Friday 19 May 2017. To submit an abstract please vist the ASM website at http://www.ads-adea.org.au/abstracts/

ASM Sponsorship:

To make enquiries into sponsoring or exhibiting at the 2017 ASM, please contact Phil McShane from ASN Events at phil@asnevents.net.au

ADS GP Education:

Category 2 RACGP QI&CPD points are available for GPs that attend certain sessions within the conference. The eligible sessions for 2017 will be made available closer to the time. There will be a form available at the registration desk at the conference for GPs to complete and to then receive the points.

Important 2017 ASM Dates to Remember:

  • Abstract submission deadline is Friday 19 May 2017
  • ADS Pincus Taft & ADS President’s Young Investigator Awards supporting documentation is required by Friday 19 May 2017
  • Earlybird Registration deadline closes on Friday 30 June 2017
  • ADS Travel Grants supporting documentation is required by Friday 30 June 2017
  • Registration to attend the 15th ADS JRT Clinical Skills Training Course closes on Monday 17 July 2017

2017 ADS Annual General Meeting

The 2017 ADS Annual General Meeting will be held on Thursday 31 August from 12:30pm to 1:00pm at the Perth Convention & Exhibition Centre, WA. All financial members of the Australian Diabetes Society are welcome to attend the Annual General Meeting.

2017 ADS/ADEA ASM Save the Date Flyer:

Please click on the 2017 ADS/ADEA ASM flyer to download.

Contact:

ASN Events Pty Ltd
Level 1, 9/397 Smith Street
Fitzroy, VIC 3065 Australia
Tel: +61 3 8658 9530
Fax: +61 3 8658 9531  
Email: lm@asnevents.net.au

Conference Website: 

You can access our Annual Scientific Meeting site at www.ads-adea.org.au or contact ASN Events on 03 8658 9530 for any further details regarding the ASM.

2017 ADS Annual Scientific Meeting Awards

A number of awards and grants are available for ADS members attending the ADS/ADEA Annual Scientific Meeting in Perth, WA.

Please ensure that you indicate (tick the appropriate boxes) during the abstract submission process via the ASM website; if you would like to be considered for any of the ADS ASM Awards.

Please see below for all ADS ASM Awards and Grants on offer for 2017:-


ADS POSTER AWARDS

ADS Poster Awards for both Basic Science and Clinical Research will be on offer during the ADS Annual Scientific Meeting in Perth, WA. ADS Poster Awards are to the value of A$500 each.

Eligibility is as follows:
1. A financial member of the ADS (Paid subs for 2017)
2. Applicant must be an early career researcher
3. You must be standing by your poster at the time of the poster session
4. Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work

To apply: Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Friday 19 May 2017

ADS ASM Awards Application Form

 

ADS-PINCUS TAFT YOUNG INVESTIGATOR AWARD

The ADS-Pincus Taft Young Investigator Award is to the value of A$2000. The finalists will be categorised into Basic Science and the award will be given to the best oral presentation by a junior ADS member at the Annual Scientific Meeting in Perth as judged by peer review and a committee appointed by the ADS Council.

Eligibility is as follows:
1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from May 2016 and Paid subs for 2017)
2. Applicant must not be more than 2 years beyond the award of a doctoral degree (PhD, MD) or fellowship (FRACP)
3. Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
4. Previous winners of this award are in-eligible to apply
5. Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award

6-8 applicants will be selected from abstracts to present in the ADS-Pincus Taft Young Investigators Session.

To apply: Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Friday 19 May 2017

 

ADS PRESIDENT'S YOUNG INVESTIGATOR AWARD

The ADS President's Young Investigator Award is to the value of A$2000. The finalists will be categorised into Clinical Research and the award will be given to the best oral presentation by a junior ADS member at the Annual Scientific Meeting in Perth as judged by peer review and a committee appointed by the ADS Council.

Eligibility is as follows:
1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from May 2016 and Paid subs for 2017)
2. Applicant must not be more than 2 years beyond the award of a doctoral degree (PhD, MD) or fellowship (FRACP)
3. Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
4. Previous winners of this award are in-eligible to apply
5. Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award

6-8 applicants will be selected from abstracts to present in ADS Presidents Young Investigators Session.

To apply: Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Friday 19 May 2017


2017 ADS Annual Scientific Meeting Travel Grants to Perth

A number of ADS Travel Grants will be awarded to junior investigators who have an abstract accepted for presentation at the ADS Annual Scientific Meeting in the Gold Coast. The number and size of grants will be determined according to the number and suitability of applications and the funds available. Applications will be prioritised using abstract review scores. It is anticipated that the awards will represent a substantial contribution to the individual's travel costs to the meeting.

Eligibility is as follows:
1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from May 2016 and Paid subs for 2017)
2. In training for a higher degree eg. PhD, MD, fellowship or medical specialty
3. Supported by a statement from the candidate's supervisor or department head indicating the nature of their present position and the availability of other sources of financial support for their travel to the Meeting

Note: Applicants must not be in receipt of a travel grant from any other body to attend the ADS meeting or a meeting in association with the ADS meeting.

Applications Closing Date: Friday 30 June 2017


To apply:
Please click on 'Apply for ADS Travel Grant' below and complete the online application form and please ensure that you upload your supporting documentation. The successful applicants will be advised in writing prior to the meeting. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Apply for ADS Travel Grant and Upload Supporting Documentation


ADS Position Statement on Insulin-requiring diabetes and recreational diving

Mervyn Kyi, Barbora Paldus, Natalie Nanayakkara, Michael Bennett, Rebecca Johnson, Catherine Meehan, Peter Colman

In 2015 the Australian Diabetes Society commissioned a working group to review and revise its position statement on scuba diving in persons with diabetes. The working group consisted of endocrinologists with an interest in type 1 diabetes, diving medical specialists, a recreational diver with diabetes and an advocate for people with type 1 diabetes.

A thorough literature review was performed and all available evidence was summarised and a new position statement was drafted. The new position statement was submitted to the ADS Council for approval.

The scope of this document is restricted to recreational (not professional) diving in line with the available evidence. It is also targeted at insulin-requiring (both type 1 and type 2) diabetes, as traditionally this group has been excluded from recreational diving. This document updates the ADS position statement in line with current evidence.

Download the full version of the ADS Insulin-requiring diabetes and recreational diving Position Statement - PDF and Appendicies - PDF (Posted: December, 2016)


ADS launches T2D Treatment Website (A New Blood Glucose Management Algorithm for Type 2 Diabetes)

As part of World Diabetes Day (14 November, 2016), the Australian Diabetes Society has launched a new interactive website aimed at improving the lives of people living with type 2 diabetes.

The T2D treatment website is the first of its kind in Australia to offer health-care clinicians a user-friendly, interactive tool to assist them in determining the best treatment option for their patients.   The launch of the website follows the release of a revised position statement by the ADS entitled, ‘A new blood glucose management algorithm for type 2 diabetes’.

This initiative involved the support of groups including the National Association of Diabetes Centres (NADC), Diabetes Australia (DA), the National Prescribing Service (NPS) and the Royal Australian College of General Practitioners (RACGP).  

Please visit http://t2d.diabetessociety.com.au to access the T2D treatment website.

ADS Position Statement on A New Blood Glucose Management Algorithm for Type 2 Diabetes

The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents.

Control of blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death.

Treatment needs to be individualised for the person with diabetes.

This should start with selection of the appropriate blood glucose and HbA1c targets, taking into account life expectancy and the wishes of the person with diabetes. A range of recently available therapies have added to our range of options for controlling blood glucose levels but this has made the clinical pathway for managing diabetes more complicated.

To assist with clinical decision making, in 2014 the Australian Diabetes Society council appointed an expert working group to draft a position statement with a focus on the results of recent randomised clinical trials. The original statement was reviewed by the ADS council (September 2014) and then sent to all ADS members for comment before publication in the Medical Journal of Australia (December 2014). In light of new randomised clinical trial evidence the statement and algorithm was updated (December, 2016).

Download the updated (December, 2016) full version of the ADS A New Blood Glucose Management Algorithm for Type 2 Diabetes Position Statement - PDF (Posted: December, 2016)


Australasian Diabetes Data Network (ADDN)

The Australasian Diabetes Data Network (ADDN) is an initiative of the Juvenile Diabetes Research Foundation (JDRF) supported by the Australasian Paediatric Endocrine Group (APEG) and the Australian Diabetes Society (ADS) to build long term clinical research capacity in Australia for people with diabetes.

ADDN has established Australia’s first national clinical research diabetes database, collecting clinical information from people with type 1 diabetes and connecting the data on an integrated, secure, custom-built platform. This rich data resource includes national-level information about type 1 diabetes, available to researchers within strict ethical and governance boundaries.

The database currently contains clinical data from children and adolescents with diabetes from seven specialist paediatric public tertiary centres across Australia. With planned expansion to adult centres, ADDN will extend its data capture and provide richer and more complete information about the natural history, clinical progression and most effective treatment regimens for all people living with type 1 diabetes.

For more information, visit the ADDN website at http://www.addn.org.au/


Australian Obesity Management Algorithm

Obesity is a complex and multi-factorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. In 2014-15, 63.4% of Australians aged 18 years and over were above normal weight, with 27.9% being obese. Obesity is associated with a broad range of complications including type 2 diabetes, cardiovascular disease, dyslipidaemia, sleep apnoea, osteoarthritis, and certain types of cancers, which significantly impair quality of life. Obesity and its related complications place a considerable financial burden on Australia. In 2014-15, the direct and indirect costs of obesity were estimated at $ 8.65 billion.

This statement has been developed by a working group with representatives from the Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand.

The aims of the document are to:

1) Assist general practitioners (GPs) in treatment decisions for non-pregnant adults with obesity

2) Provide a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia.

Download the full version of the Australian Obesity Management Algorithm - PDF (Posted: October, 2016)


CATAG releases guiding principles on governance of biological and biosimilar medicines

The Council of Therapeutic Advisory Groups (CATAG, www.catag.org.au) has updated and released the following document.,‘Overseeing biosimilar use. Guiding Principles for the governance of biological and biosimilar medicines in Australian hospitals’ Version 2 (September 2016). CATAG is cognisant the governance and management of biosimilars medicines is an evolving area and has reviewed its guidance in the context of national and international developments, including the outcome of the TGA review. The purpose of the Guiding Principles is to provide guidance for good governance and decision-making in relation to the use of biological therapies within Australian public hospitals. The guidance is intended to provide an overall framework, which is encouraged to be implemented locally. The guidance consists of nine Guiding Principles, which address the importance of governing the selection, prescription, switching, patient involvement, monitoring and communication of biologic/biosimilar use. The updated version 2 of the biosimilar Guiding Principles includes two significant changes. The document is available through the CATAG website at www.catag.org.au and can be downloaded as a PDF.


  • Updated driver medical standards from 1 October 2016

    While many factors contribute to safety on the road, driver health and fitness to drive is an important consideration. Drivers must meet certain medical standards to ensure their health status does not unduly increase their crash risk. Assessing Fitness to Drive, a joint publication of Austroads and the National Transport Commission (NTC), details the medical standards for driver licensing for use by health professionals and driver licensing authorities. The standards are approved by Commonwealth, state and territory transport ministers. In October 2016, new medical standards come into effect for drivers of private and commercial vehicles. The NTC website provides information for health professionals, employers, heavy vehicle drivers, commercial drivers and private vehicle drivers. Please click on the link to download the free electronic pdf version at https://www.onlinepublications.austroads.com.au/items/AP-G56-16



    TOUJEO® insulin now available in Australia on private prescription

    TOUJEO® (300 units/mL) will be available in Australia as a private prescription for the treatment of diabetes mellitus in adults as of 1 December 2016.

    Toujeo® SoloStar® is a prefilled pen that contains a longer-acting1 formulation of insulin glargine (300 units/mL) compared with Lantus® (insulin glargine 100 units/mL). Toujeo is designed for once-daily subcutaneous administration. Toujeo (300 units/mL) will appear in commonly used script writing software.

    Toujeo is not currently available on the Pharmaceutical Benefits Scheme (PBS) and will not be available at a PBS-subsidised price, so patients will incur out of pocket costs. We recommend advising patients to check with their pharmacist to determine the cost of having their Toujeo prescription dispensed.

    It is important to note that this strength of insulin glargine (300 units/mL [Toujeo]) is not bioequivalent and therefore not automatically interchangeable to other basal insulins and will require dose adjustment.

    For information about price, guidance on how to initiate a patient on Toujeo and to access an educational leaflet for patients, please download these resources via the following links (Private Supply Notice - PDF / Patient Carer Guide - PDF / Healthcare Professional Guide - PDF)

    To find out more about Toujeo, visit the website at https://www.toujeo.com.au


    Important TGA update on Metformin

    The TGA has issued an update on the availability status of Metformin.

    The following products are now available: 

    • DIABEX XR 500 metformin hydrochloride 500 mg extended release tablet blister pack
    • DIAFORMIN XR metformin hydrochloride 500 mg extended release tablet blister pack
    • DIABEX XR 1000 metformin hydrochloride 1000 mg extended release tablet blister pack
    • DIAFORMIN XR 1000 metformin hydrochloride 1000 mg extended release tablet blister pack.

    The current status of shortages and affected products is outlined in the table below:

    197405

    CHEMMART METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack

    Apotex Pty Ltd

    Limited availability

    197402

    APO-METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack

    Apotex Pty Ltd

    Limited availability

    197406

    TERRY WHITE CHEMISTS METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack

    Apotex Pty Ltd

    Limited availability

    143464

    METEX XR metformin hydrochloride 500 mg extended release tablet blister pack

    Arrow Pharma Pty Ltd

    Limited availability

    The TGA also advises pharmacists that, if they are unable to obtain Metformin extended release products that are currently available through their regular wholesaler, they should contact an alternative wholesaler to try to secure stock.

    Medicine Recall: Certain Batches of GlucaGen HypoKit in Australia

    Novo Nordisk Pharmaceuticals Pty Ltd is recalling certain batches of GlucaGen® HypoKit due to a small number of needles becoming detached from the pre-filled syringe supplied in the GlucaGen® HypoKit

    Novo Nordisk Pharmaceuticals Pty Ltd is recalling for batches of GlucaGen® HypoKit in Australia. GlucaGen® HypoKit is used for the treatment of severe hypoglycaemic reactions which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. This action has been undertaken following consultation with the Therapeutic Goods Administration (TGA). Novo Nordisk conducted an investigation showing a small number (0.006%) of needles from certain batches may become detached from the pre-filled syringe supplied during use. Despite the very low risk to patient safety, Novo Nordisk is recalling all products in the affected batches from wholesalers, pharmacies and patients in Australia.

    The recalled GlucaGen® HypoKit batch numbers and expiry date in Australia are:

    Batch Number

    Expiry date

    FS6X465

    31-Aug-2017

    FS6X536

    31-Aug-2017

    FS6X715

    31-Aug-2017

    FS6X891

    31-Aug-2017

    Note that community and hospital pharmacies will also be contacted and requested to follow up with patients they have supplied since February 2016 and will be asked to return any stock they hold from affected batches. Formal notification has also been sent to mainstream national media, professional diabetes/endocrine societies, RACGP, RACP and diabetes patient associations. If patients have a GlucaGen® HypoKit from an affected batch they are to return it to their pharmacy. They will be given a free replacement either immediately (if the pharmacy has unaffected stock available) or within a few days (if the pharmacy has to await resupply). If the pharmacy does not receive a replacement immediately, the patient is to retain their GlucaGen® HypoKit until the replacement can be provided, as the likelihood of a detached needle is very low. Importantly, if you are in possession of GlucaGen® HypoKit products with batch numbers NOT mentioned above there is NO concern and you can be confident that the products will work as prescribed. Further information: NovoCare® Customer Care Centre Phone: 1800 668 626 Email: aunrccc@novonordisk.com Website: www.novonordisk.com.au


    Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

    The ADS has recently endorsed international guidelines that recommend metabolic surgery for patients with type 2 diabetes and class III (BMI ≥40 kg/m2) obesity and patients with type 2 diabetes with class II (BMI 35.0–39.9 kg/m2) obesity who have had inadequate glycaemic control with lifestyle and pharmacotherapy.

    Download the full version of the 'Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations' Guidelines - PDF (Posted: June, 2016)


    2016 ADS Membership Renewal

    The 2016 Australian Diabetes Society Membership Fee Renewals are now overdue. Please ensure that the ADS Secretariat has all the correct mailing and contact details, particularly email addresses, as we rely on these to maintain contact with you and keep you informed of ADS activities. The 2016 ADS Subscription period is from 1 July 2016 to 30 June 2017. Please contact the ADS secretariat at admin@diabetessociety.com.au for membership enquiries.


    Enhancing Your Consulting Skills - Now available for download online

    “Enhancing Your Consulting Skills: Supporting self-management and optimising mental health in people with type 1 diabetes” is designed for trainees in Adult Endocrinology, their supervisors and other interested health professionals. The resource includes topics such as information giving, health literacy, facilitating practical skills acquisition, and promoting behaviour change. It also explores the emotional, psychological and psychiatric issues that can impact on the quality of life of people with type 1 diabetes.

     

    “Enhancing Your Consulting Skills” was developed by the Australian Diabetes Society for the National Diabetes Services Scheme. It is now available in electronic format through the ADS website at: [http://diabetessociety.com.au/download-request.asp]. It can be downloaded free of charge for individual use. Please Note that you will be required to submit a request for download and obtain your password prior to receiving the download link. Hard copies of the resource are available from the ADS Secretariat.



    Important Information regarding changes to the National Diabetes Services Scheme

    From 1 July 2016 some important changes are happening to the National Diabetes services Scheme (NDSS). There are no changes to the types of products available under the NDSS, but the way people access these products may change. People will still be able to access NDSS products through their local participating community pharmacy access point. In fact the Federal Government wants to extend the number of community pharmacies that provide NDSS products to make it more convenient for people with diabetes. NDSS products will no longer be available through Diabetes Australia (DA) or state and territory diabetes organisations. This means people will no longer be able to order products via the Diabetes Australia shops, the NDSS 1300 number or via the website. Diabetes Australia and state and territory diabetes organisations will instead focus efforts on continuing to provide education services for people with diabetes. There will be no changes to NDSS education services funded by the Government - in fact the Government will be increasing funding to expand education and support available to people with diabetes. Community Pharmacies have made up more than 90% of all NDSS access points in Australia for over ten years, so people can be confident that if they have not accessed pharmacy before for this, they will receive a high level of service.

    Please visit the Department of Health website for the latest updates or click here to read the NDSS Frequently Asked Questions.


    Australian National Diabetes Strategy 2016-2020

    The Australian Government has developed and released a new National Diabetes Strategy to update and priorities the national response to diabetes across all levels of government. The Australian National Diabetes Strategy 2016-2020 (the Strategy) is a high-level document that contains a number of goals and potential areas for action that provide a range of ideas for implementation to achieve each goal. This presents a range of opportunities for jurisdictions to partner with the Commonwealth to develop and support approaches for diabetes prevention and control. The Strategy was endorsed by the Australian Health Ministers Advisory Council (AHMAC) on 2 October 2015, noted by the COAG Health Council on 6 November 2015, and publically released 13 November 2015. An implementation plan will be developed in consultation with jurisdictions through AHMAC to consider the ways to direct funding and other resources and proposed measures to evaluate the progress of the Strategy. Engagement and support from jurisdictions will facilitate a coordinated approach to diabetes across governments and ensure there is broad benefit from the Strategy. The Strategy has been informed by the expert advice of the National Diabetes Strategy Advisory Group and consultations with key stakeholders and the community. The Australian Government provides support to people with diabetes through Medicare and a range of programs and this new Strategy will not replace or override existing processes. This Strategy aims to better coordinate health resources across the sector to where they are needed most. The Australian National Diabetes Strategy document is available from the Department of Health's website at http://www.health.gov.au/internet/main/publishing.nsf/Content/nds-2016-2020 Media Release Statement by Health Minister; the Hon Sussan Ley MP on Australia delivers new National Diabetes Strategy on World Diabetes Day


    The Australian Diabetes Society endorses Endocrinology, Diabetes & Metabolism Case Reports

    Endocrinology, Diabetes & Metabolism Case Reports is a unique, open access resource that publishes and links together case reports, enabling practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively; furthering both medical education and clinical practice. The search and browse functionality enables fluid navigation between case reports, facilitating discovery, connections and comparisons; making it the go-to resource across all the many disciplines intersecting with endocrinology, diabetes and metabolism.

    Members of the Australian Diabetes Society receive a 20% discount on the open access publishing charge when publishing case reports in Endocrinology, Diabetes & Metabolism Case Reports (submit online via www.edmcasereports.com).

    Please click on the PDF link to download and view the member flyer - PDF